Combined Pulmonary Fibrosis and Emphysema: When Scylla and Charybdis Ally

Cells. 2023 Apr 28;12(9):1278. doi: 10.3390/cells12091278.

Abstract

Combined pulmonary fibrosis and emphysema (CPFE) is a recently recognized syndrome that, as its name indicates, involves the existence of both interstitial lung fibrosis and emphysema in one individual, and is often accompanied by pulmonary hypertension. This debilitating, progressive condition is most often encountered in males with an extensive smoking history, and is presented by dyspnea, preserved lung volumes, and contrastingly impaired gas exchange capacity. The diagnosis of the disease is based on computed tomography imaging, demonstrating the coexistence of emphysema and interstitial fibrosis in the lungs, which might be of various types and extents, in different areas of the lung and several relative positions to each other. CPFE bears high mortality and to date, specific and efficient treatment options do not exist. In this review, we will summarize current knowledge about the clinical attributes and manifestations of CPFE. Moreover, we will focus on pathophysiological and pathohistological lung phenomena and suspected etiological factors of this disease. Finally, since there is a paucity of preclinical research performed for this particular lung pathology, we will review existing animal studies and provide suggestions for the development of additional in vivo models of CPFE syndrome.

Keywords: CPFE; animal models; emphysema; lung fibrosis.

Publication types

  • Review

MeSH terms

  • Emphysema* / complications
  • Humans
  • Hypertension, Pulmonary*
  • Lung / pathology
  • Male
  • Pulmonary Emphysema* / complications
  • Pulmonary Emphysema* / diagnostic imaging
  • Pulmonary Emphysema* / pathology
  • Pulmonary Fibrosis* / complications
  • Pulmonary Fibrosis* / pathology

Grants and funding

This research received no external funding.